Annual report pursuant to Section 13 and 15(d)

Organization, Plan of Business Operations (Details)

v3.21.1
Organization, Plan of Business Operations (Details) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended
Feb. 08, 2019
Dec. 31, 2020
Dec. 31, 2019
Nov. 12, 2018
Cash and cash equivalents   $ 3,132 $ 8,745  
Milestone Payments   5,000    
Accumulated deficit   $ 73,268 $ 68,117  
Line of Credit [Member]        
Interim Financing Amount $ 7,000      
Invagen Pharmaceuticals Inc [Member]        
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned $ 31,500     $ 215,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares 5,833,333      
Business Acquisition, Share Price $ 6.00      
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners 33.30%      
Invagen Pharmaceuticals Inc [Member] | Common Shares        
Stock Issued During Period, Value, Acquisitions $ 180,000